<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983800</url>
  </required_header>
  <id_info>
    <org_study_id>UHN 13-5845</org_study_id>
    <nct_id>NCT01983800</nct_id>
  </id_info>
  <brief_title>AnaConDa Long Term Sedation Study</brief_title>
  <acronym>VALTS</acronym>
  <official_title>Use of Volatile Anesthetics for Long-Term Sedation In Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heavy sedation or sleep is a common problem within the intensive care unit (ICU) using our
      standard intravenous medications. This commonly leads to confusion, low blood pressure, slow
      wake up and removal of the artificial breathing tube (extubation), which prolongs ICU stay.
      Using inhaled volatile anesthetic agents are likely to improve these patient outcomes. This
      unique project is the first North American study looking at using volatiles for patients who
      need longer-term ICU sedation. This project has excellent potential at lowering these
      complications and improving quality of care, which will lower patient ICU stay and
      healthcare costs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>atmospheric volatile concentration</measure>
    <time_frame>daily</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Daily assessment of atmospheric volatile levels will be measured using photometric multigas infrared analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation</measure>
    <time_frame>daily</time_frame>
    <safety_issue>No</safety_issue>
    <description>adherence to the volatile sedation, sedation will be guided by explicit protocols targeting a Sedation-Agitation Score (SAS) of 3-4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assess rate of patient recruitment and barriers to recruitment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Education Tool</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>multidisciplinary feedback regarding teaching package, protocol, quality of sedation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum fluoride levels</measure>
    <time_frame>every 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurements will be taken 24 hours post sedation and every 48 hours until extubation or 30 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intubated Requiring Sedation for Greater Than 48 Hours</condition>
  <arm_group>
    <arm_group_label>intravenous propofol/midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <arm_group_label>isoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol/midazolam</intervention_name>
    <arm_group_label>intravenous propofol/midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult ICU patients expected to be ventilated &gt; 48 hours

        Exclusion Criteria:

          -  age &lt; 18 years

          -  history of malignant hyperthermia

          -  propofol infusion syndrome

          -  evidence of raised intracranial pressure

          -  6-month mortality risk from pre-existing condition &gt; 50%

          -  lack of commitment to maximal treatment

          -  pregnant

          -  if on Flolan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Jerath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital, University Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Jerath, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3242</phone_ext>
    <email>angela.jerath@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo Carroll</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>jo.carroll@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John MacDonald, MD</last_name>
      <phone>613-761-4379</phone>
      <email>jmacdonald@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Denyse Winch</last_name>
      <email>dwinch@ottawaheart.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Jerath, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>3242</phone_ext>
      <email>angela.jerath@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Angela Jerath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcin Wasowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niall Ferguson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Steel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duminda Wijeysundera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Flockhart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Rao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Mazer, MD</last_name>
      <phone>416-864-5825</phone>
      <email>mazerd@smh.toronto.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Volatile Sedation</keyword>
  <keyword>Intravenous Sedation</keyword>
  <keyword>Delirium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
